Shelton Capital Management’s Takeda Pharmaceutical TAK Stock Holding History

Shelton Capital Management’s Portfolio TAK Stock Details TAK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-10,068	Closed	-$184K	–	858
2021 Q1	$184K	Hold	10,068	–	–	0.01%	785
2020 Q4	$183K	Hold	10,068	–	–	0.01%	698
2020 Q3	$180K	Hold	10,068	–	–	0.01%	706
2020 Q2	$181K	Hold	10,068	–	–	0.01%	606
2020 Q1	$153K	Sell	10,068 -65	-0.6%	-$1.18K	0.01%	569
2019 Q4	$200K	Sell	10,133 -35,600	-78%	-$681K	0.01%	772
2019 Q3	$787K	Hold	45,733	–	–	0.05%	253
2019 Q2	$809K	Buy	45,733 +44,801	+4,807%	+$815K	0.05%	256
2019 Q1	$45.7K	Buy	+932	New	+$18.8K	0.18%	125

Other funds holding TAK

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

GCM

Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

PPA

Parametric Portfolio Associates Seattle, Washington $190B AUM 18.52% 1-Year Est. Return

MIP

Mondrian Investment Partners London, United Kingdom $6.69B AUM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Shelton Capital Management's TAK Position: Q2 2021 in Review

Shelton Capital Management sold out of Takeda Pharmaceutical (TAK) in Q2 2021, closing a stake of 10,068 shares — an estimated $184K sold.

Shelton Capital Management first reported a position in TAK in Q1 2019 and held it in 9 quarters. The position peaked at $809K in Q2 2019. 304 funds tracked by Wall St. Rank hold TAK as of Q2 2021.

Shelton Capital Management reported no remaining Takeda Pharmaceutical position as of Q2 2021 after selling out during the quarter.
Shelton Capital Management sold 10,068 Takeda Pharmaceutical shares in Q2 2021, an estimated $184K.
Shelton Capital Management first reported a position in Takeda Pharmaceutical in Q1 2019 and held it in 9 quarters.
Shelton Capital Management's Takeda Pharmaceutical position peaked at $809K in Q2 2019.
304 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q2 2021.

Based on Shelton Capital Management's 13F filing for Q2 2021, filed 12 Aug 2021.